Current Report Filing (8-k)
July 13 2022 - 4:52PM
Edgar (US Regulatory)
0000910267
false
0000910267
2022-07-12
2022-07-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): July 12, 2022
Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341 |
94-3171940 |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
(Address of principal executive offices and zip code)
650-244-4990
(Registrant's telephone number including area code)
(Registrant's former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
Common Stock, $0.001 par value |
TTNP |
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On July 12, 2022,Titan Pharmaceuticals, Inc. (the “Company”)
received a request from Activist Investing LLC to change the meeting date for the previously announced special meeting of the Company’s
stockholders from August 2, 2022 to August 15, 2022.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: July 13, 2022 |
TITAN PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/
Kate Beebe DeVarney, Ph.D. |
|
|
Name: Kate Beebe DeVarney, Ph.D. |
|
|
Title: Chief Operating Officer
and President |
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Sep 2023 to Sep 2024